FDA approves first single-entity, extended-release hydrocodone drug

Agency announces approval of Zogenix's Zohydro ER

SILVER SPRING, Md. — The Food and Drug Administration has approved a new opioid painkiller made by Zogenix, the agency said Friday.

The FDA announced the approval of Zohydro ER (hydrocodone) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term treatment. The agency said the drug was the first extended-release hydrocodone product not combined with another drug, such as acetaminophen, to be approved by the agency.

Because it is a so-called single-entity hydrocodone product, Zohydro ER is listed as a Schedule II controlled substance. Drugs that combine no more than 15 mg of hydrocodone with another analgesic, such as AbbVie's Vicodin, are Schedule III drugs, though the FDA said this week that it would recommend those products for CII scheduling as well.

Poll

Poll

Which of the current U.S. Presidential hopefuls do you think would be best for your business?

Hillary Clinton

Jeb Bush

Donald Trump

Ted Cruz

Ben Carson

Scott Walker

Marco Rubio

Rand Paul

Chris Christie

Mike Huckabee

SPECIAL REPORTS

Pharmacy’s battle for recognition continues

Fifty years ago this summer, President Lyndon B. Johnson secured his place in history by signing into law the legislation that created Medicare and Medicaid. To commemorate the anniversary, Drug Store News has put together an exclusive report on the effect that Medicare and Medicaid have had on the retail pharmacy industry and how it has transformed the role of the pharmacist. more...

IN THIS ISSUE

In this issue, DSN profiles Rite Aid and how the company is achieving a vision to become a retail healthcare company that delivers a higher level of care to its communities; takes you on a tour of Sears; offers insight into millennial shoppers and more. Click here to view the issue.